Follow Lumenci:
Intuitive Surgical, Inc. is a US-based medical technology company and the pioneer of robotic-assisted surgery, with a patent portfolio spanning surgical robotics, teleoperated manipulator arms, endoscopic instruments and end effectors, surgical visualization and 3D imaging, instrument wristing and articulation, force feedback and haptics, catheter-based and endoluminal navigation, surgeon consoles and user interfaces, sterile interfaces and drapes, and surgical data and analytics. Its filings cover master-slave control architectures, remote centre-of-motion kinematics, tool-tracking and image-guided navigation, fluorescence imaging, stapling and energy instruments, and digital tools for surgical training and workflow. The company develops the da Vinci surgical system family, including da Vinci 5 and da Vinci SP, and the Ion endoluminal platform, and the portfolio includes patents filed across multiple decades and jurisdictions covering a broad range of minimally invasive care technologies.
Intuitive Surgical’s patent portfolio comprises 9,901 patents distributed across 1,995 simple families and 1,729 extended families. The portfolio spans 25 jurisdictions and includes patents associated with surgical robotics, instrument design, visualization and imaging, navigation, control systems, and related medical device technologies.
New Analysis Monthly Alerts. No Spam!
Intuitive Surgical’s portfolio consists of 7,196 active assets and 2,696 inactive assets. Active holdings include 5,145 granted patents and 2,051 patent applications. Inactive assets comprise expired patents, patents expired due to term or maintenance fee non-payment, withdrawn applications, and abandoned applications.
Intuitive Surgical’s patents span 25 jurisdictions, with the United States accounting for the largest share of filings and grants.
Total Patents: 9,901
The portfolio includes patent assets across North America, Asia, and Europe, with the largest concentration located in the United States. Substantial holdings in China, the European Patent Office, Japan, and South Korea reflect Intuitive’s international expansion and the principal markets for robotic-assisted surgical systems.
Intuitive Surgical’s patent portfolio is overwhelmingly concentrated in healthcare, reflecting its focus on surgical robotics, instruments, and minimally invasive care. Secondary domains include computer systems and components covering robotic control hardware and manipulator systems, software covering surgical planning and data analytics, and imaging covering endoscopic visualization and fluorescence technologies.
Intuitive Surgical’s litigation dataset includes 46 patents that have been involved in litigation matters, 27 petitions, 2 reexaminations, and 15 Chinese Patent Reexamination Board proceedings. The dataset also includes 3 active cases, 21 inactive cases, 24 appeals, and 11 related parties.
Intuitive Surgical’s patent portfolio consists of 9,498 originally assigned patents and 403 acquired patents, indicating a predominantly organically developed portfolio. Acquired patents originate largely from operating companies, with smaller contributions from universities and other sources.
Intuitive Surgical has grown primarily through internal research and development rather than large-scale acquisitions, a pattern reflected in the portfolio’s 96% originally assigned share. Its principal corporate transactions have been targeted technology acquisitions and joint ventures supporting market access.
Intuitive acquired Orpheus Medical, an Israel-based developer of surgical video capture, management, and integration software, expanding its digital and data capabilities across the operating room.
Intuitive established a joint venture with Shanghai Fosun Pharmaceutical to develop and manufacture robotic-assisted catheter-based technologies for the Chinese market, supporting local regulatory approval and market access in one of its fastest-growing regions.
Intuitive Surgical, Inc., which trades as Intuitive, is a publicly listed medical technology company on the Nasdaq (ISRG) and is a component of the S&P 500 and Nasdaq-100. It is the pioneer and market leader in robotic-assisted surgery through its da Vinci surgical system family and the Ion endoluminal platform.
Intuitive Surgical, Inc.
1020 Kifer Road
Sunnyvale, CA 94086
United States
Intuitive Surgical’s global headquarters are located in Sunnyvale, California.
Intuitive Surgical’s patent portfolio includes 9,901 patents across 25 jurisdictions. The portfolio contains patent assets in surgical robotics, teleoperated manipulator systems, endoscopic instruments and end effectors, surgical visualization and imaging, endoluminal navigation, surgeon consoles, and surgical data and analytics.
The portfolio includes 1,995 simple families, 1,729 extended families, 11 litigated patents, and 8 challenged patents, with 7,196 active assets of which 2,051 are pending applications.
Intuitive Surgical’s patent portfolio includes 9,901 patents across 25 jurisdictions. The portfolio contains patent assets in surgical robotics, teleoperated manipulator systems, endoscopic instruments and end effectors, surgical visualization and imaging, endoluminal navigation, surgeon consoles, and surgical data and analytics.
The portfolio includes 1,995 simple families, 1,729 extended families, 11 litigated patents, and 8 challenged patents, with 7,196 active assets of which 2,051 are pending applications.
Intuitive Surgical’s patent portfolio contains 9,901 patents across 25 jurisdictions. The portfolio includes 1,995 simple families and 1,729 extended families.
Healthcare accounts for roughly 84% of the portfolio, covering surgical robotics, instruments, and minimally invasive care, followed by computer systems and components at about 7% and software at roughly 4%.
Intuitive Surgical’s portfolio includes 7,196 active patent assets, consisting of 5,145 active grants and 2,051 active applications.
The United States contains the largest number of Intuitive Surgical patent assets, followed by China, the European Patent Office, World Intellectual Property Organization filings, Japan, and South Korea.
The litigation dataset includes 46 patents in litigation, 27 petitions, 24 appeals, 2 reexaminations, and 15 Chinese PRB proceedings.
The portfolio contains 9,498 originally assigned patents and 403 acquired patents, meaning roughly 96% of the portfolio was developed internally.
The citation data includes significant references involving Johnson & Johnson, Medtronic, Olympus, Stryker, Boston Scientific, Karl Storz, Philips, and Siemens.
Dave Rosa has served as President and Chief Executive Officer since 1 July 2025, succeeding Gary Guthart, who led the company from 2010 and now serves as Executive Chair of the board.
Reach out and we’ll get you what you need.
By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively.
Close
